Full FDA approval history for liraglutide (Victoza, Saxenda), covering every indication, label expansion, boxed warning, post-market safety update, and generic entry from 2010 through 2025.
A clinical review of liraglutide's regulatory history, current FDA label, generic pipeline status, and next-generation GLP-1 receptor agonists positioned to follow it.
A clinical review of liraglutide safety signals reported through the FDA Adverse Event Reporting System (FAERS), including pancreatitis, gallbladder events, thyroid concerns, and acute kidney injury.
A clinical review of low-dose naltrexone (LDN) regulatory status worldwide, including FDA-approved naltrexone labeling, 503A compounding pharmacy rules, and off-label prescribing frameworks in the US, EU, UK, and Australia.
A clinical and regulatory review of LDN's off-label legal status, compounding pharmacy oversight, patent barriers, and the FDA approval gap that keeps low-dose naltrexone without a dedicated label.
Current FDA regulatory status of low-dose naltrexone (LDN), ongoing clinical trials, compounding pharmacy access, and what next-generation formulations may change for patients.
A side-by-side comparison of how the FDA and EMA regulate metformin, including approval history, label differences, renal thresholds, safety monitoring, and post-market surveillance.
A complete timeline of metformin's FDA approval, label expansions, safety reviews, and regulatory milestones from 1994 to the present day.
A complete overview of metformin's regulatory history across the FDA, EMA, and other global agencies, including approval timelines, labeling updates, NDMA concerns, and current prescribing status.
A clinical review of metformin safety signals in the FDA Adverse Event Reporting System (FAERS), including lactic acidosis, B12 deficiency, NDMA contamination, and updated renal dosing guidance.
A clinical review of MK-677 (ibutamoren) safety signals in the FDA Adverse Event Reporting System, including hyperglycemia risk, edema, regulatory status, and trial-level evidence.
MOTS-c has no FDA approval and remains an investigational mitochondrial-derived peptide. Review the preclinical pipeline, safety signals, regulatory outlook, and what published research actually shows about this novel metabolic peptide.
MOTS-c has no FDA approval, no FAERS profile, and no official drug label. Here is what the regulatory landscape looks like for this mitochondrial-derived peptide and what safety data actually exists.
Mounjaro EMA product information: tirzepatide was authorised EU-wide on 15 September 2022, and the SmPC now covers type 2 diabetes and weight management.
Every FDA label change for Mounjaro (tirzepatide) from initial approval through 2026, including new indications, boxed warnings, safety communications, and post-market requirements.
A clinical guide to the regulatory status of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), covering FDA decisions, compounding pharmacy rules, dietary supplement classification, and safety data.
Current regulatory status of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) across major markets including FDA classification, EMA position, TGA scheduling, and dietary supplement rules.
A complete regulatory timeline for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) from 2020 through 2026, covering FDA determinations, supplement status, clinical trial evidence, and current labeling rules.
Current regulatory status of NMN and NR (nicotinamide mononucleotide and nicotinamide riboside), active clinical trials, FDA decisions, and the next-generation NAD+ precursor pipeline.
Analysis of FDA FAERS and CAERS safety signal data for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), including clinical trial adverse event profiles and post-market surveillance limitations.
A full regulatory timeline of oral minoxidil, from its 1979 FDA approval for hypertension to its off-label use in low-dose hair loss therapy, including label requirements and safety data.
A comprehensive review of oral minoxidil's regulatory status worldwide, including FDA approval history for hypertension, off-label low-dose prescribing for hair loss, and how regulators in Australia, the EU, and beyond handle this drug.
A clinical overview of the oral minoxidil regulatory pipeline, upcoming trials, next-generation formulations, and the future of low-dose oral minoxidil for hair loss treatment.
A guide to the legal status of compounded semaglutide (Ozempic), FDA shortage declarations, 503A/503B pharmacy rules, and what changes mean for patients in 2026.
A clinical comparison of how the FDA and EMA regulate Ozempic (semaglutide), covering approval timelines, label differences, boxed warnings, post-market surveillance, and safety monitoring frameworks.
Every FDA label change to Ozempic (semaglutide 0.5-2.0 mg) from 2020 through 2026, including new warnings, dose expansions, and post-market safety signals.
A detailed review of bremelanotide (Vyleesi) FDA adverse event reports, FAERS safety signals, labeling updates, and post-market surveillance findings for clinicians and patients.
A comparison of how the FDA and EMA regulate sirolimus (Rapamune), covering approved indications, boxed warnings, post-market surveillance, and why neither agency's approval says anything about off-label longevity use.
A detailed review of every major FDA label change to rapamycin (sirolimus) between 2020 and 2026, including new safety warnings, dosing revisions, and post-market surveillance findings.
A clinical review of sirolimus regulatory history, current off-label longevity research, next-generation rapalogs in development, and what the FDA pipeline means for patients in 2026.
Every FDA label change for Rybelsus (oral semaglutide) from initial approval through 2026, including safety communications, boxed warning revisions, and new indications.
A clinical review of Rybelsus (oral semaglutide) regulatory history, current FDA label, post-market safety data, and Novo Nordisk's next-generation oral GLP-1 pipeline.
A detailed review of Rybelsus (oral semaglutide) safety signals from the FDA Adverse Event Reporting System (FAERS), including gastrointestinal events, pancreatitis, thyroid concerns, and gallbladder disorders.
A clinical breakdown of Saxenda (liraglutide 3 mg) compounding legality, FDA approval history, shortage list status, and the 503A/503B framework that governs compounded GLP-1 medications.
Saxenda's FDA NDA number is 206321, approved December 23, 2014. See the timeline, label changes, pediatric expansion, and post-market safety warnings.
A clinician-focused review of Saxenda (liraglutide 3 mg) regulatory approvals across FDA, EMA, and other global agencies, including label details, post-market safety signals, and prescribing requirements.
A complete timeline of Saxenda (liraglutide 3 mg) FDA label updates from 2020 through 2026, including new safety warnings, boxed label revisions, post-market study results, and prescribing changes.
A clinical review of sermorelin acetate's regulatory history, current compounding status, and the next-generation GHRH analogs and GH secretagogues in development that may reshape growth hormone therapy.
A clinical breakdown of spironolactone's FDA approval history, current label indications, compounding legality under federal 503A and 503B frameworks, and the evidence base for off-label acne prescribing.
Spironolactone has been used off-label for hormonal acne for decades, yet no FDA-approved acne indication exists. Explore the legal, patent, and regulatory barriers that keep this drug in off-label territory.
A clinical review of spironolactone's regulatory history, current off-label acne use, emerging topical formulations, and next-generation antiandrogens in development for hormonal acne.
A clinical review of spironolactone adverse event reports in the FDA's FAERS database, covering hyperkalemia, hormonal effects, the black box warning, and monitoring guidance for off-label acne use.
A clinical comparison of how the FDA and EMA approve and monitor generic tadalafil (2.5-20 mg), including bioequivalence standards, label requirements, post-market surveillance, and safety data.
A clinical and regulatory overview of the legal battles, patent disputes, and FDA approval history behind generic tadalafil 2.5-20 mg, including Paragraph IV litigation, authorized generics, and post-market safety considerations.
How the FDA and EMA each handle TB-500 (thymosin beta-4 active fragment), why it remains unapproved in both jurisdictions, and what that means for compounding access and clinical research.
TB-500 (thymosin beta-4 active fragment) has never received FDA approval. Learn its full regulatory history, compounding pharmacy access rules, and clinical safety data.
TB-500 (thymosin beta-4 fragment) faces unique legal and patent challenges as an unregulated peptide. Learn about FDA enforcement, compounding pharmacy access, WADA bans, and the regulatory pathway ahead.
A clinical overview of tesamorelin (Egrifta) compounding legality, FDA approval history, shortage designations, and what patients and providers need to know about access in 2026.
A detailed review of FDA label changes for Egrifta and Egrifta SV (tesamorelin) from 2020 through 2026, including updated warnings, post-marketing safety data, and clinical guidance, with sourcing notes on where a claim still needs independent verification.
A clinical breakdown of testosterone cypionate safety signals reported to the FDA Adverse Event Reporting System (FAERS), including cardiovascular events, polycythemia, liver injury, and what the data means for patients on TRT.
A clinical guide to testosterone enanthate's FDA approval history, compounding regulations under Section 503A and 503B, label requirements, and safety monitoring for TRT patients.
A complete timeline of FDA label changes for testosterone enanthate from 2020 through 2026, including cardiovascular warnings, REMS modifications, and post-market surveillance data.
A clinical review of testosterone enanthate's FDA history, patent status, labeling changes, REMS requirements, and ongoing legal disputes affecting prescriber and patient access.
A detailed analysis of testosterone enanthate safety signals reported through the FDA Adverse Event Reporting System (FAERS), including cardiovascular events, polycythemia, venous thromboembolism, and current label warnings.
A detailed comparison of how the European Medicines Agency and the U.S. Food and Drug Administration regulate thymosin alpha-1 (thymalfasin), including approval status, compounding access, and safety data.
A clinical review of thymosin alpha-1 (thymalfasin) regulatory status, FDA approval history, ongoing pipeline developments, and next-generation formulations for immune modulation.
A detailed analysis of Thymosin Alpha-1 (thymalfasin) safety signals from the FDA Adverse Event Reporting System (FAERS), including reported adverse events, signal-to-noise ratios, and clinical context for prescribers.
A side-by-side comparison of how the FDA and EMA regulate topical minoxidil 5%, covering approval history, labeling differences, OTC status, safety monitoring, and post-market surveillance.
A detailed review of FDA approval history, patent disputes, generic competition, and ongoing regulatory issues surrounding topical minoxidil 5% for hair loss treatment.
A clinical review of topical minoxidil's regulatory history, current FDA-approved formulations, pipeline innovations, and next-generation delivery systems for androgenetic alopecia.